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These findings demonstrated a correlation between the presence of branched chain amino acids (BCAAs) in the serum and radiographic severity of OA.
There is an increasing body of evidence describing the role of the synovium in the progression of OA. To our knowledge, metabolic profiling has not been applied to synovial tissue culture or synovial fluid. The purpose of the current study was to obtain the global metabolic profile of osteoarthritic synovium in order to identify the presence of metabolites that may serve as novel biomarkers of OA.
METHODS:
Tissue collection and preparation. Synovium was collected from patients undergoing total knee arthroplasty for end-stage OA ("end-stage OA" group, n=11; to-be-discarded surgical waste, IRB exempt) or from patients undergoing knee surgery to repair a torn ligament or meniscus with minimal isolated or no evidence of cartilage damage ("early OA" group, n=11). This group was meant to serve as a normal control. Samples were kept sterile upon collection, dissected to ~3 mm 3 , weighed, and placed into individual culture tubes containing 2 ml of sterile culture media (LG-DMEM (Gibco), 10% FBS (Hyclone), 5 ml Pen-Strep (100 U/100 µg), and 25 mM HEPES buffer. Samples, along with separate control tubes containing media only (n=8), were cultured for 48 hours. Media was collected at the end of the culture period for analysis as described below.
Metabolic profiling. The non-targeted metabolic profiling platform employed for this analysis (Metabolon, Inc.; Durham, NC) combined three independent platforms: ultrahigh performance liquid chromatography/tandem mass spectrometry (UHLC/MS/MS 2 ) optimized for basic species, UHLC/MS/MS 2 optimized for acidic species, and gas chromatography/mass spectrometry (GC/MS).
Metabolites were identified by automated comparison of the ion features in the experimental samples to a reference library of 2000+ chemical standard entries that included retention time, molecular weight (m/z), preferred adducts, and in-source fragments as well as associated MS spectra and were curated by visual inspection for quality control using software developed at Metabolon.
Statistical analysis. Welch's two-sample t-tests were used to identify biochemicals with relative concentrations that differed significantly between early OA and end-stage OA groups compared to media control, as well as to identify biochemicals that differed between the disease stage groups. An estimate of the false discovery rate (q-value) was calculated to take into account the multiple comparisons that normally occur in metabolomic-based studies; as q-values were reasonable for p≤0.05, no q-value cutoff was established for this study.
RESULTS:
One hundred five metabolites were detected across all samples. A total of 13 compounds differed significantly between the early OA and end-stage OA groups, with 9 compounds that were elevated in the endstage OA group compared to the early OA group, while 4 were depressed (Table 1 ). An additional 8 metabolites that exhibited differences between end-stage and early OA groups at p < 0.1 are also provided in Table 1 . Several of these compounds are of particular interest. First, the 2.52 fold increase in heme (a product of hemoglobin catabolism) likely represents increased vascularity in the end-stage OA samples. Second, pro-hydroxyproline is a metabolic product of collagen degradation 2 and its elevated presence in end-stage OA is consistent with a profile of more advanced proteolysis in that disease process. Additionally, metabolic breakdown products BCAAs were found to be lower in the end-stage OA group compared to early OA group, including 4-methoxy-2-oxopentanoate (p<0.05) and 3-methyl-2-oxobutyrate (0.05<p<0.1); indicating decreased catabolism of the BCAAs leucine and valine with increased disease.
BCAA concentrations have previously been shown to increase with radiographic evidence of OA in patient serum. 1 Findings also demonstrated that acetylcarnitine and succinate, two products involved in energy metabolism, were elevated in the end-stage OA group suggesting a compromised ability to properly metabolize collagen, glucose, and BCAA's. Additionally glutamine was significantly elevated in the end-stage OA group. Glutamine is required for oxidative metabolism; thus, elevated glutamine suggests a decrease in oxidative metabolism in diseased tissue. Moreover, elevated glutamine could also point to a decrease in GAG production, as glutamine is required for the production of GAG.
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In addition to these findings, ~ 50 compounds were found to be significantly different (elevated or depressed) between early OA or endstage OA and media control groups. Of interest were findings that synovium obtained from all groups secreted compounds involved in the tryptophan metabolism pathway including tryptophan and it's metabolite, kynurenine, which suggests a heightened state of response to inflammation.
DISCUSSION:
Metabolic profiling of explanted synovial tissue culture demonstrated a distinct metabolic profile of end-stage OA. Metabolites involved with collagen degradation, AA/BCAA catabolism, energy metabolism, and lipid and carbohydrate metabolism were found to be significantly different in tissue cultures from patients with end-stage OA compared to those of patients with little or no evidence of disease. These metabolites may serve as novel biomarkers for OA diagnosis or to monitor disease progression. 
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